Ionis Pharmaceuticals vs Kiniksa Pharmaceuticals International
Ionis Pharmaceuticals is the larger business, with $944m of revenue in fiscal 2025 against $678m for Kiniksa Pharmaceuticals International (1.4 times as much). Kiniksa Pharmaceuticals International grew faster (60.1% against 33.8%). Kiniksa Pharmaceuticals International kept more of each dollar of sales as profit: a net margin of 8.7% against -40.4%. Kiniksa Pharmaceuticals International carries less debt relative to equity (0.0% against 370.6%).
| Latest fiscal year | Ionis PharmaceuticalsIONS, 2025 | Kiniksa Pharmaceuticals InternationalKNSA, 2025 |
|---|---|---|
| Revenue | $944m | $678m |
| Revenue growth | 33.8% | 60.1% |
| Net income | −$381m | $59.0m |
| Operating margin | -40.4% | 11.4% |
| Net margin | -40.4% | 8.7% |
| Return on equity | -70.8% | 11.7% |
| Free cash flow | −$320m | $136m |
| Cash | $372m | $166m |
| Total debt | $1.81bn | $0 |
| Debt to equity | 370.6% | 0.0% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 1,402 | 366 |
| Market value | $6.75bn | $7.91bn |
| Price vs our value range | — | Above our value range |
| Moat score | 35 (Weak) | 16 (Weak) |
| Insider trades, 12 months | 2 buys, 116 sales | 0 buys, 37 sales |